Session » Sjögren's Syndrome II: Clinical Discoveries

Date: Tuesday, November 10, 2015

Time: 4:30PM-6:00PM

Meeting: 2015 ACR/ARHP Annual Meeting

4:30PM-6:00PM: Abstract Number: 3200

Characterization of Early and Progressive Autoimmunity in Sjogrens Syndrome: The Incomplete Sjogrens Syndrome Model

4:30PM-6:00PM: Abstract Number: 3202

Functional Anti-Muscarinic Receptor-3 Monoclonal Antibodies Derived from Salivary Gland in Patients of Sjögren’s Syndrome

4:30PM-6:00PM: Abstract Number: 3204

Hypoechoic Lesions on Parotid Gland Ultrasound Are a Surrogate Marker of Focal Lymphocytic Sialadenitis on Minor Salivary Gland Biopsy in Sjögren’s Syndrome

4:30PM-6:00PM: Abstract Number: 3201

IL-7 Drives Cytokine Secretion of IL-7Rabright CCR9-Expressing T-Follicular Helper-like Cells: Potential New Axis in Lymphoid Neogenesis in Salivary Glands of Primary Sjogren s Syndrome Patients

4:30PM-6:00PM: Abstract Number: 3203

The Clinical Efficacy and Safety of Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, in Primary Sjögren’s Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Trial

4:30PM-6:00PM: Abstract Number: 3205

Treatment with Abatacept or Rituximab Targets T Follicular Helper Cells in Patients with Primary Sjogren s Syndrome

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].